Skip to main content
. 2014 Jan 7;20(1):148–162. doi: 10.3748/wjg.v20.i1.148

Table 1.

Demographic, virological and histological data of patients included in the trial n (%)

Control group Group E6 Group E9 Group L6 Group L9
Demographics1 and virological response
n = 30 n = 16 n = 16 n = 15 n = 15
Age (yr) mean ± SD 48.5 ± 7.4 47.4 ± 9.1 42.6 ± 7.9 47.3 ± 7.5 45.3 ± 7.3
Sex Feminine 12 (40) 11 (68.8) 8 (50.0) 11 (73.3) 9 (60)
Masculine 18 (60) 5 (31.3) 8 (50.0) 4 (26.7) 6 (40)
Body Mass Index mean ± SD 26.7 ± 2.8 24.8 ± 3.5 28.6 ± 4.6 25.3 ± 5.0 24.9 ± 4.4
Race White 16 (53.3) 12 (75.0) 11 (68.8) 10 (66.7) 8 (53.3)
Black 4 (13.3) 3 (18.8) 3 (18.8) 4 (26.7) 3 (20.0)
Mixed 10 (33.3) 1 (6.3) 2 (12.5) 1 (6.7) 4 (26.7)
Response to treatment2 cEVR 18 (60.0) 10 (62.5) 9 (56.3) 7 (46.7) 4 (26.7)
SVR 14 (46.7) 8 (50) 8 (50) 7 (46.7) 2 (13.3)
Histology3
Week 0 n 30 16 16 15 15
Necroinflammation mean ± SD 6.7 ± 3.6 6.4 ± 3.2 6.1 ± 3.3 5.1 ± 3.4 7.0 ± 4.1
Fibrosis 1.6 ± 1.4 1.9 ± 1.3 1.4 ± 1.4 1.6 ± 1.3 2.3 ± 1.8
Week 72 n 19 13 14 9 8
Necroinflammation mean ± SD 3.3 ± 2.5 3.8 ± 2.2 3.2 ± 2.8 4.9 ± 3.0 5.6 ± 3.2
Fibrosis 1.3 ± 1.5 2.1 ± 1.3 1.1 ± 1.3 2.1 ± 1.6 2.5 ± 1.6
1

Corresponding to baseline;

2

By intention to treat;

3

According to Ishak score[17]. cEVR: Complete early viral responders; SVR: Sustained viral responders.